The UK Prospective Diabetes Study, a large clinical trial performed in 1980-90s, provided evidence that metformin reduced the rate of adverse cardiovascular outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents. Treatment guidelines for major professional associations including the European Association for the Study of Diabetes, the European Society for Cardiology and the American Diabetes Association, now describe evidence for the cardiovascular benefits of metformin as equivocal. In 2017, the American College of Physicians's guidelines were updated to recognize metformin as the first-line treatment for type-2 diabetes. For example, a 2014 review found tentative evidence that people treated with sulfonylureas had a higher risk of severe low blood sugar events (RR 5.64), though their risk of non-fatal cardiovascular events was lower than the risk of those treated with metformin (RR 0.67). There was not enough data available at that time to determine the relative risk of death or of death from heart disease. study known as the Diabetes Prevention Program, participants were divided into groups and given either placebo, metformin, or lifestyle intervention and followed for an average of three years. Metformin treatment of people at a prediabetes stage of risk for type 2 diabetes may decrease their chances of developing the disease, although intensive physical exercise and dieting work significantly better for this purpose. The intensive program of lifestyle modifications included a 16-lesson training on dieting and exercise followed by monthly individualized sessions with the goals of decreasing weight by 7% and engaging in physical activity for at least 150 minutes per week. The incidence of diabetes was 58% lower in the lifestyle group and 31% lower in individuals given metformin. Among younger people with a higher body mass index, lifestyle modification was no more effective than metformin, and for older individuals with a lower body mass index, metformin was no better than placebo in preventing diabetes. Metformin is a commonly used treatment modality in type 2 diabetes mellitus, with a well documented side effect of lactic acidosis. In the intensive care setting lactate and p H levels are regularly used as a useful predictor of poor prognosis. In this article we highlight how high lactate levels are not an accurate predictor of mortality in deliberate metformin overdose. We present the case of a 70-year-old Caucasian man who took a deliberate metformin overdose of unknown quantity. He had a profound lactic acidosis at presentation with a p H of 6.93 and a lactate level of more than 20mmol/L. These figures would normally correspond with a mortality of more than 80%; however, with appropriate management this patient’s condition improved. We provide evidence that the decision to treat severe lactic acidosis in deliberate metformin overdose should not be based on arterial lactate and p H levels, as would be the case in other overdoses.
Acute metformin overdose: Examining serum p H lactate Levels and metformin concentrations in survivors versus nonsurvivors: A systematic review of the literature. Annals of Emerg Med 2009; 54: 818-23 Metformin, a blood-glucose-lowering drug widely used for treatment of type 2 diabetes, is associated with risk of potentially fatal metabolic (lactic) acidosis. This can occur not only following overdose but also at therapeutic dose in patients with pre-existing renal or liver disease. Results of arterial blood gas analysis reflect metabolic acidosis (reduced blood p H, reduced bicarbonate compensatory increase in ) and increased plasma lactate. Is it possible, as might be intuitively expected, to predict survival in such cases from the severity of the acidosis and/or severity of the hyperlactatemia? Investigators conducted a systematic review of the literature and identified 22 well-documented case histories of metformin overdose, five of which had a fatal outcome. For each of these cases, investigators abstracted lowest (nadir) p H, highest (peak) plasma lactate concentration and highest (peak) plasma metformin concentration. The median nadir p H among non-survivors was 6.71 (interquartile IQ range 6.71-6.73), this compared with median p H 7.30 (IQ range 7.22-7.36) for survivors. In the setting of breathlessness at rest or on minimal exertion from conditions such as advanced cancer or end-stage cardiorespiratory diseases, regular, low-dose sustained-release morphine significantly reduces breathlessness safely, with its benefits maintained over time. Like loperamide and other opioids, morphine acts on the myenteric plexus in the intestinal tract, reducing gut motility, causing constipation. The gastrointestinal effects of morphine are mediated primarily by μ-opioid receptors in the bowel. By inhibiting gastric emptying and reducing propulsive peristalsis of the intestine, morphine decreases the rate of intestinal transit. Reduction in gut secretion and increased intestinal fluid absorption also contribute to the constipating effect. Opioids also may act on the gut indirectly through tonic gut spasms after inhibition of nitric oxide generation. Clinical studies consistently conclude that morphine, like other opioids, often causes hypogonadism and hormone imbalances in chronic users of both sexes.
– organiczny związek chemiczny, dimetylowa pochodna biguanidu. Jest lekiem z grupy biguanidów, stosowanym jako doustny lek przeciwcukrzycowy. Jest wykorzystywany w leczeniu cukrzycy typu 2, szczególnie jeśli towarzyszy jej nadwaga lub otyłość W medycynie ludowej od czasów średniowiecza stosowano roślinę rutwicę lekarską (Galega officinalis), której przypisywano działanie przeciwcukrzycowe. Z naturalnie występujących w rutwicy biguanidów, guanidyna okazała się zbyt toksyczna, za to galeginę stosowano przez krótki czas na początku XX wieku jako lek przeciwcukrzycowy. W toku dalszych badań, w 1926 r., udało się uzyskać 2 syntetyczne biguanidy: syntalinę A i B, charakteryzujące się jeszcze lepszą od galeginy tolerancją. Ze względu na odkrycie i szerokie zastosowanie insuliny jako leku przeciwcukrzycowego zarzucono na wiele lat stosowanie i badania nad tą grupą leków hipoglikemizujących. Metformina czyli dimetylobiguanid, został odkryty i zastosowany w leczeniu cukrzycy w 1957 roku przez francuskiego lekarza Jeana Sterne'a. Polycystic ovary syndrome (PCOS) is a complex condition affecting approximately 10 percent of women of childbearing age. Women with PCOS can experience a variety of symptoms ranging from mood changes and skin conditions (acne, excess facial hair) to irregular periods and fertility problems. The medications used PCOS aim to alleviate the symptoms of the disease. While there is currently no cure for PCOS, you can minimize the impact of the disease by maintaining a healthy lifestyle and managing symptoms with the selective use of drugs. PCOS is characterized by hormonal abnormalities that can result in infrequent periods (oligomenorrhea) or absent periods (amenorrhea). These and other hormonal irregularities can undermine a woman's ability to get pregnant. Drug treatment is aimed at regulating hormones to better restore a normal menstrual cycle.
Aug 2, 2012. We present the case of a 70-year-old Caucasian man who took a deliberate metformin overdose of unknown quantity. He had a profound lactic. Jan 16, 2015. Metformin - Get up-to-date information on Metformin side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about.